This content is not available in your region

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Access to the comments Comments
Text size Aa Aa

(Reuters) – Biogen Inc said on Monday it would buy back shares worth $5 billion (3.8 billion pounds), days after its stock slumped on the drugmaker’s announcement to end two Alzheimer’s disease trials.

Biogen had lost more than $18 billion of its value last week after the company and partner Eisai Co Ltd ended two late-stage trials of their experimental Alzheimer’s disease treatment, aducanumab.

Biogen shares, which lost 32.4 percent of their value since the company’s announcement on Thursday to scrap the trials, were up 1.5 percent before the opening bell on Monday.

The share buyback is in addition to the approximately $1.7 billion remaining under the stock repurchase programme authorised by its board in August 2018, the company said in a regulatory filing

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.